Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.

Azelastine, an antiallergy and antiasthmatic drug, has been reported to be metabolized mainly to desmethylazelastine and 6-hydroxyazelastine in mammals. In the present study, the inhibitory effects of azelastine and its two metabolites on human cytochrome P-450 (CYP) isoform-dependent reactions were investigated to predict the drug interactions of azelastine using microsomes from human B-lymphoblast cells expressing CYP. The specific activities for human CYP isoforms included: 7-ethoxyresorufin O-deethylation (CYP1A1), phenacetin O-deethylation (CYP1A2), coumarin 7-hydroxylation (CYP2A6), 7-benzyloxyresorufin O-dealkylation (CYP2B6), S-warfarin 7-hydroxylation (CYP2C9), S-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), and testosterone 6beta-hydroxylation (CYP3A4). In almost all the activities, desmethylazelastine exhibited stronger inhibition than azelastine and 6-hydroxyazelastine. Desmethylazelastine, but not azelastine and 6-hydroxyazelastine, uncompetitively inhibited CYP2B6 activity (Ki = 32.6 +/- 4.8 microM). Azelastine, desmethylazelastine, and 6-hydroxyazelastine competitively inhibited CYP2C9 activity (Ki = 13. 9 +/- 1.8, 15.0 +/- 3.1, and 17.0 +/- 4.1 microM, respectively), CYP2C19 activity (Ki = 21.9 +/- 2.2, 7.3 +/- 1.6, and 9.3 +/- 1.6 microM, respectively), and CYP2D6 activity (Ki = 1.2 +/- 0.1, 1.5 +/- 0.2, and 3.0 +/- 0.5 microM, respectively). Azelastine and desmethylazelastine competitively inhibited CYP3A4 activity (Ki = 23. 7 +/- 4.6 and 13.2 +/- 2.3 microM). 6-Hydroxyazelastine interfered with the determination of testosterone 6beta-hydroxylation by HPLC. CYP1A2, CYP2A6, and CYP2E1 activities were not significantly inhibited by azelastine and the two metabolites. Among the human CYPs tested, the inhibitory effects of azelastine and its two metabolites were the most potent on human CYP2D6. In consideration of the Ki values and the concentration of azelastine and desmethylazelastine in human livers after chronic oral administration of azelastine, the possibility of in vivo drug interaction of azelastine and other drugs that are mainly metabolized by CYP2D6 was suggested although it might not cause critical side effects. The inhibition of CYP2C9, CYP2C19, and CYP3A4 activity by azelastine and its two metabolites might be clinically insignificant.

[1]  W. Trager,et al.  Lack of Effect of Azelastine and Ketoconazole Coadministration on Electrocardiographic Parameters in Healthy Volunteers , 1997, Journal of clinical pharmacology.

[2]  A. Guillouzo,et al.  Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. , 1993, Chemical research in toxicology.

[3]  D. Waxman,et al.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. , 1988, Archives of biochemistry and biophysics.

[4]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[5]  R. Sofia,et al.  Pharmacokinetics of azelastine and its active metabolite, desmethylazelastine, in guinea pigs. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[6]  A. Parkinson,et al.  Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. , 1992, Archives of biochemistry and biophysics.

[7]  F. Guengerich.  Characterization of roles of human cytochrome P-450 enzymes in carcinogen metabolism , 1990 .

[8]  P. Beaune,et al.  Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. , 1991, Chemical research in toxicology.

[9]  R. Böcker,et al.  Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. , 1995, Journal of chromatography. B, Biomedical applications.

[10]  H. Yamazaki,et al.  Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[11]  K. Chiba,et al.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. , 1998, British journal of clinical pharmacology.

[12]  T Yamamoto,et al.  Involvement of CYP1A2 in mexiletine metabolism. , 1998, British journal of clinical pharmacology.

[13]  T. Kronbach,et al.  High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. , 1987, Analytical biochemistry.

[14]  H. Yamazaki,et al.  Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[15]  W. Jaeger,et al.  Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.

[16]  Tsuyoshi Inoue,et al.  CYTOCHROME P 450 2 C 9 CATALYZES INDOMETHACIN O-DEMETHYLATION IN HUMAN LIVER MICROSOMES , 1998 .

[17]  C. Sengstag,et al.  Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[18]  L. Prescott.  Pharmacokinetic drug interactions. , 1969, Lancet.

[19]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[20]  R. Sofia,et al.  Metabolism of [14C]azelastine in guinea pigs. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[21]  R. Tukey,et al.  Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. , 1993, The Journal of pharmacology and experimental therapeutics.

[22]  M. Brodie,et al.  Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? , 1985, British journal of clinical pharmacology.

[23]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[24]  S. Tokudome,et al.  Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[25]  D. Greenblatt,et al.  Biotransformation of Chlorzoxazone by Heptatic Microsomes from Humans and Ten Other Mammalian Species , 1997, Biopharmaceutics & drug disposition.

[26]  R. Sofia,et al.  Determination of azelastine and desmethylazelastine in human plasma by high-performance liquid chromatography. , 1987, Journal of chromatography.

[27]  T. Shimada,et al.  Purification and characterization of human liver microsomal cytochrome P-450 2A6. , 1991, Molecular pharmacology.

[28]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[29]  M. Brodie,et al.  Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. , 1981, Biochemical pharmacology.

[30]  H. Yamada,et al.  Metabolism of an antiallergic agent, azelastine (4-(p-chlorobenzyl)-2-[N-methylperhydroazepinyl-(4)]-1-(2H)-p hthalazin one hydrochloride) in rats and guinea pigs. , 1984, Hiroshima journal of medical sciences.

[31]  L. Kaminsky,et al.  Human P450 metabolism of warfarin. , 1997, Pharmacology & therapeutics.

[32]  M. P. Arlotto,et al.  Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. , 1991, Methods in enzymology.

[33]  N. Winslade,et al.  Pharmacokinetic drug interactions , 1987 .

[34]  H. Yamada,et al.  Studies of metabolic fate of a new antiallergic agent, azelastine (4-(p-chlorobenzyl)-2-[N-methylperhydroazepinyl-(4)]-1-(2H)-phthalazinone hydrochloride). , 1980, Japanese journal of pharmacology.